Eilean Therapeutics
Clinical trials sponsored by Eilean Therapeutics, explained in plain language.
-
New drug ZE74-0282 targets rare blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests an experimental drug, ZE74-0282, in about 60 adults with polycythemia vera or myelofibrosis caused by a specific JAK2 gene mutation. The main goals are to find a safe dose and check for side effects, while also seeing if the drug shows signs of fighti…
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
A new molecule enters human testing: can ZE66-0205 prove safe?
Knowledge-focused Not yet recruitingThis first-in-human trial tests the safety and tolerability of a single dose of the experimental drug ZE66-0205 in healthy adults aged 18 to 55. Researchers will also measure how the drug moves through the body and how it affects MALT1 levels in blood cells. Participants are rand…
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC